As of March 23, 2026, Soleno Therapeutics's top three insider holders are Andrew Sinclair (Director, 18.02Mn shares), Opportunity, Llc Vivo (TenPercentOwner, 4.46Mn shares), Group Inc. Carlyle (TenPercentOwner, 1.53Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Andrew Sinclair | 0 | 18,022,602 | 31 Mar, 2022 | |
| Opportunity, Llc Vivo | 0 | 4,458,294 | 28 Mar, 2025 | |
| Group Inc. Carlyle | 0 | 1,531,436 | 02 Oct, 2023 | |
| Bhatnagar Anish | Chief Executive Officer | 583,656 | 0 | 23 Jan, 2026 |
| James H Mackaness | Chief Financial Officer | 131,763 | 0 | 23 Jan, 2026 |
| Meredith Manning | Chief Commercial Officer | 72,029 | 0 | 23 Jan, 2026 |
| Michael F. Huang | Sr. Vp Of Clinical Development | 46,405 | 0 | 23 Jan, 2026 |
| Jennifer Fulk | Chief Financial Officer | 39,200 | 0 | 04 Mar, 2026 |
| Kristen Yen | See Remarks | 37,639 | 0 | 23 Jan, 2026 |
| Patricia C Hirano | See Remarks | 22,702 | 0 | 23 Jan, 2026 |
| Manher Joshi | Chief Development Officer | 20,171 | 0 | 23 Jan, 2026 |
| William G Harris | 19,392 | 0 | 09 Jun, 2025 | |
| Kevin Norrett | Chief Business Officer | 17,786 | 0 | 23 Jan, 2026 |
| Birgitte Volck | 17,536 | 0 | 09 Jun, 2025 | |
| Dawn Carter Bir | 16,991 | 0 | 09 Jun, 2025 | |
| Andrew Sinclair | 10,491 | 0 | 09 Jun, 2025 | |
| Matthew Pauls | 10,491 | 0 | 09 Jun, 2025 | |
| Mark W Hahn | 10,046 | 0 | 14 Oct, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 02 Mar, 2026 | Jennifer Fulk | Common Stock | A | 39,200 | $0.00 | 39,200 | D | A |
| 02 Mar, 2026 | Jennifer Fulk | Employee stock option (right to buy) | A | 67,660 | $0.00 | 67,660 | D | M |
| 21 Jan, 2026 | James H Mackaness | Common Stock | A | 28,600 | $0.00 | 131,763 | D | A |
| 21 Jan, 2026 | Meredith Manning | Common Stock | A | 28,600 | $0.00 | 72,029 | D | A |
| 21 Jan, 2026 | Kristen Yen | Common Stock | A | 10,400 | $0.00 | 37,639 | D | A |
| 21 Jan, 2026 | Patricia C Hirano | Common Stock | A | 10,400 | $0.00 | 22,702 | D | A |
| 21 Jan, 2026 | Michael F. Huang | Common Stock | A | 10,400 | $0.00 | 46,405 | D | A |
| 21 Jan, 2026 | Kevin Norrett | Common Stock | A | 3,500 | $0.00 | 17,786 | D | A |
| 21 Jan, 2026 | Bhatnagar Anish | Common Stock | A | 114,200 | $0.00 | 583,656 | D | A |
| 21 Jan, 2026 | Manher Joshi | Common Stock | A | 4,100 | $0.00 | 20,171 | D | A |
| 21 Jan, 2026 | Meredith Manning | Employee stock option (right to buy) | A | 32,800 | $0.00 | 32,800 | D | A |
| 21 Jan, 2026 | Kevin Norrett | Employee stock option (right to buy) | A | 4,000 | $0.00 | 4,000 | D | A |
| 21 Jan, 2026 | Manher Joshi | Employee stock option (right to buy) | A | 4,700 | $0.00 | 4,700 | D | A |
| 21 Jan, 2026 | James H Mackaness | Employee stock option (right to buy) | A | 32,800 | $0.00 | 32,800 | D | A |
| 21 Jan, 2026 | Michael F. Huang | Employee stock option (right to buy) | A | 11,900 | $0.00 | 11,900 | D | A |
| 21 Jan, 2026 | Kristen Yen | Employee stock option (right to buy) | A | 11,900 | $0.00 | 11,900 | D | A |
| 21 Jan, 2026 | Bhatnagar Anish | Employee stock option (right to buy) | A | 131,400 | $0.00 | 131,400 | D | A |
| 21 Jan, 2026 | Patricia C Hirano | Employee stock option (right to buy) | A | 11,900 | $0.00 | 11,900 | D | A |
| 15 Dec, 2025 | James H Mackaness | Common Stock | D | 2,013 | $49.95 | 103,163 | D | F |
| 15 Dec, 2025 | Kristen Yen | Common Stock | D | 904 | $49.95 | 27,239 | D | F |